Evaluation of Postoperative Serum CA19-9 in Hepatobiliary and Pancreatic Malignancies
Raj Kumar Bhatta1, Swati Rajput2*, Manisha Naithani3, L. Kaman1, Arunanshu Behera1, Divya Dahiya1, Satyavati Rana2
1Department of General Surgery, PGIMER, Chandigarh, India.
2Department of Biochemistry, All India Institute of Medical Sciences, Vijayapur, Jammu, India.
3Department of Biochemistry, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.
Citation: Bhatta RK, Rajput S, Naithan M, Kaman L, Behera A et al (2023) Evaluation of Postoperative Serum CA19-9 in Hepatobiliary and Pancreatic Malignancies. SciTech Biomed-Cancer 2023.
Received: November 15, 2023 Accepted: November 17, 2023 Published: November 17, 2023
Abstract
Objectives:
- To determine the value of serum CA 19-9 in the diagnosis of Hepatobiliary and Pancreatic Malignancies
- To determine the value of serum CA 19-9 in the follow up of Hepatobiliary and Pancreatic Malignancies
- To correlate the change in preoperative and postoperative serum levels of CA 19-9 with the surgical resection limit.
Methodology: This prospective observational study was carried out at the Department of General Surgery, PGIMER Chandigarh in 31 patients. Statistical comparisons between pre and postoperative values were carried out using a chi-square test with statistically significant p values.
Results: The postoperative decrease in the levels of CA 19-9 ranges from 24 U/ml to 174 U/ml. The mean postoperative levels of serum CA19-9 were 87.6 U/ml for the carcinoma pancreas group. Maximum and minimum drop in CA 19-9 levels was seen in carcinoma head of pancreas cases and duodenal adenocarcinoma group respectively. The mean difference of CA19-9 with SD in Ca head of the pancreas, carcinoma gallbladder and Distal CBD cholangiocarcinoma was 789.09 + 207.95 U/ml, 388 + 163.17 U/ml and 124.5 + 56.47 respectively at 95% CI with statistically significant p-value (0.00, 0.006 and 0.02)
Conclusion: Serial measurement of this tumour marker can be done in patients to assess response to therapy who undergo curative surgical resection.
